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Next Generation SequencingAbstract Background: Acute myeloid leukemia (AML) is a heterogeneous clonal disorder in
terms of cytogenetic and molecular aberrations. Ten-Eleven-Translocation 2 (TET2), Kirsten rat
sarcoma viral oncogene homolog (KRAS), and Casitas B-cell lymphoma (CBL) have an important
role pathogenesis of acute myeloid leukemia (AML) and their activated mutations confer prolifer-
ative and survival signals.
Aim: In this study, we aimed to find possible genetic markers for molecular analysis in childhood
AML by screening hot-spot exons of TET2, KRAS, and CBL using Next Generation Sequencing
(NGS) analysis. In addition, association between found variants and mutations of Januse
Kinase-2 (JAK2) and Fms-Related Tyrosine Kinase (FLT3) were analyzed which are important
prognostic risk factors for AML.
Methods: Eight patients who were diagnosed with pediatric AML at Losante Pediatric Hematol-
ogy–Oncology Hospital were included to the study. Hot-spot exons ofTET2, KRAS and CBL genes
were screened using the NGS method. Furthermore, FLT3-Internal Tandem Duplicate (FLT3-ITD)
and JAK2-V617F were analyzed by Real Time Polymerase chain Reaction (Real Time-PCR).a Yolu,
210 D.F. Akin et al.Results: In total, we identified 20 variants in studied genes by NGS. In our patient group, 16
variants in the TET2 (seven novel, seven missense and two silent), two variants in the KRAS
(one missense and one intronic) and two variants in the CBL (two novel) were found. All of
AML patients were found negative for JAK V617 F. Three of the eight patients (37.5%) showed
mutations of both FLT3-ITD and TET2, KRAS, CBL.
Conclusion: We found novel mutations forTET2, KRAS, and CBL. The detected variants in this
article seem to be the first screening results of genes studied by NGS in childhood AML patients.
Our results also showed some degree of association between FLT3-ITD and TET2, KRAS, CBL
mutations.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
AML is a heterogeneous clonal neoplasm characterized by
accumulated genetic aberrations, which causes enhanced pro-
liferation, maturation arrest, increased survival of the leukemic
blast cells and variable response to therapy [1–5].
During the past decades, a number of recurrent cytogenetic
and molecular genetic abnormalities have been identified in
AML such as t(8;21), inv(16), FLT3, NPM1, CEBPA, TET2,
KRAS, and CBL.
TET family gene members (TET1, TET2, and TET3) have
functions mostly in hematopoietic differentiation. The TET
oncogene family member 2 (TET2) gene located at chromo-
some band 4q24 catalyzes the conversion of 5-methylcytosine
to 5-hydroxymethylcytosine [1,6,7]. TET2 mutations are fre-
quently detected during progression of MPN (myeloprolifera-
tive neoplasms) or MDS (myleodysplastic syndromes) to AML
[1]. TET2 mutations may contribute to leukemogenesis by
altering epigenetic regulation of transcription via DNA methy-
lation. The incidence of TET2 mutations is approximately 10–
20% in AML [2].
RAS (Rat Sarcoma Virus) proteins including HRAS (Har-
vey Rat Sarcoma Viral Oncogene Homolog),KRAS andNRAS
(Neuroblastoma RAS Viral V-Ras Oncogene Homolog) are
members of the small GTPases superfamily [8]. Abnormal
RAS function is related to hyperproliferative developmental
diseases and cancers [2]. RAS mutations, especially KRAS,
represent about 90% of cancer-associated mutations. RAS
proteins play a major role in cell signaling pathway of cell
proliferation, differentiation, and survival [9]. The RAS muta-
tions are the most common mutations in AML which are seen
in approximately 25–44% of patients. Among RAS mutations,
KRAS mutations are the most frequently seen and found in
10–15% of these patients [10].
CBL, CBL-B, and CBL C/3 are the members of the CBL
which is localized on human chromosome 11 q23 containing
several functional domains [11]. CBL is a mammalian gene
encoding the protein CBL which is an E3 ubiquitin-protein
ligase involved in cell signaling and protein ubiquitination.
Mutations of this gene have been implicated in a number of
human cancers, particularly in AML. These mutations have
also been observed in 1% of AML. CBL mutations have been
reported in myeloid malignancies and uniformly affect either
the linker region or the RING finger domain. Loss of
ubiquitination of activated receptor tyrosine kinases is
thought to contribute to the transforming potential of
leukemia-associated mutant CBL proteins [12].JAK2 (located in chromosome 9p24) encodes a cytoplasmic
tyrosine kinase. JAK2V617F presents a somatic point muta-
tion (including exon 12 of the JAK2) resulting in the substitu-
tion of valine by phenylalanine amino acid at codon 617. This
mutation, which causes JAK homology 2 (JH2) negative regu-
latory domain, derails JAK2 kinase regulatory activity which
effects cytokine independent proliferation of hematopoietic
cells [13]. The JAK2 V617F mutation is found in 1.8–28% of
patients with AML [14].
FMS-like tyrosine kinase 3 (FLT3) is a member of the
receptor tyrosine kinase (RTK) III subfamily. The FLT3
receptor gene (located in chromosome 13q12) encodes a 993
amino acid protein. This protein is expressed in bone marrow,
thymus and lymph nodes [15]. FLT3 plays a major role in cell
survival, proliferation, and differentiation of hematopoietic
stem cells [16]. FLT3-ITD is found in about one quarter of
newly diagnosed AML patients. This mutation causes the main
activation of the receptor tyrosine kinase activity in the
absence of ligand [17].
In our study, we aimed to screen whole TET2, KRAS, and
CBL by NGS analysis, evaluating the association of mutations
of JAK2 and FLT3 which is known as prognostic risk factors
and finding possible genetic markers for molecular leukemia
analysis. The NGS method is a powerful tool to discover novel
disease mutations and candidate biomarkers. Therefore we
chose NGS as a screening method for our study.
2. Subjects and methods
2.1. Subjects
The study population consisted of eight patients aged between
one and 15 years who were admitted to Losante Hospital for
Children with Leukemia with the diagnosis of AML. An
informed written consent was obtained from all the patients’
parents. Patient characteristics of the eight pediatric AML
cases are shown in Table 1.
2.2. Cytogenetic techniques
Bone marrow samples were collected with Heparin-containing
tubes, and chromosome analysis was performed using
G-banding. After the slide preparation, G-banding using
Giemsa-staining was carried out according to the standard
procedures. On each slide 20 metaphases were analyzed by a
light microscope (Nikon, JAPAN). Karyotypes were described
according to ISCN [24].
Table 1 Demographic characteristics and TET2, KRAS, and CBL variants of children with AML.
No Gender/
age/
Diagnosis FAB Risk
group
Cytogenetics-Molecular abnormalities TET2 CBL KRAS FLT3
ITD
Rs
number
Nucleotide
change
Localization Amino
acid
change
Rs
number
Nucleotide
change
Localization Amino
acid
change
Rs
number
Nucleotide
change
Localization Amino
acid
change
1 M/13 AML M4 HR 46, XY, monosomy, Trisomy 14 Novel 5284
A> G
Exon 11 Leu-
Val
– – – – – – – – Negative
2 M/13 AML M1 HR t(9;22) Rs
12498609
86 G > C Exon 3 Pro-
Arg
Rs
17851045
182 A > T Exon 3 Gln-
Leu
– – – – Negative
Rs
111836509
310 A>C Exon 3 Tyr-Ser
3 F/8 AML M5 SR 46, XX Rs
17253972
1088
C > T
Exon 3 Pro-
Leu
– – – Novel 1347 T del Exon 8 Gly- Gly Negative
Novel 1842 G del Exon 3 Gly-
Gly
Rs
142173406
5162
T > G
Exon 11 Ser-Ser
Novel 46 A del Exon 4 –
Novel 730 A del Exon 3 Trp-His
4 F/3 AML
+ T-
ALL
M4 HR 47, XX (+21) c 21 der(14) (14q1,2?q 3,2ii
1q21? q43),der(19)(19qtel)?
p13.3::11q13)11qtel [9]. t(9,22)
Rs
200327850
2286
C > T
Exon 3 Pro-
Leu
Rs
111836509
310 A > C Exon 3 Tyr-
Stop
Novel 1347 T del Exon 8 Gly-Gly Positive
Rs
112576862
2386
G> C
Exon 3 Ser-Ser
Rs
17253972
1088
C > T
Exon 3 Pro-
Leu
Novel 1842 G del Exon 3 Gly-
Gly
Rs
142173406
5162
T > G
Exon 11 Ser-Ser
Novel 46 A del Exon 4 –
Novel 730 A del Exon 3 –
5 M/3 AML M4 SR 46, XY, monosomy 7 Novel 1842 G del Exon 3 Gly-
Gly
Rs
111836509
310 A > C Exon 3 Tyr-
Stop
Novel 1347 T del Exon 8 Gly- Gly Positive
Novel 46 A del Exon 4 –
Novel 730 A del Exon 3 –
Rs
144386291
2599
T > C
Exon 3 His-
Arg
Novel 5343
A> G
Exon 11 His-Val
Rs
372499795
5164
C > T
3’ UTR Thr-ile
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Table 1 (continued)
No Gender/
age/
Diagnosis FAB Risk
group
Cytogenetics-Molecular abnormalities TET2 CBL KRAS FLT3
ITD
Rs
number
Nucleotide
change
Localization Amino
acid
change
Rs
number
Nucleotide
change
Localization Amino
acid
change
Rs
number
Nucleotide
change
Localization Amino
acid
change
6 M/7 AML M4 HR 47, XY,+ 22[12] Inv (16;16), Fragile X
syndrome
Rs
17253972
1088
C > T
Exon 3 Pro-
Leu
– – – – Novel 1347 T del Exon 8 Gly- Gly Negative
Novel 1842 G del Exon 3 Gly-
Gly
Rs
142173406
5162
T > G
Exon 11 Leu-
Trp
Novel 46 A del Exon 4 –
Rs
150298743
100 C > T Exon 3 Trp-_Ile
Rs
68431410
652 G > A Exon 3 Val-
Met
Novel 5333
A> G
Exon 11 His-
Arg
7 F/9 AML M2 SR 46, XX Novel 1842 G del Exon 3 Gly-
Gly
Rs
111836509
310 A > C Exon 3 Tyr-
Stop
Novel 1347 T del Exon 8 Gly- Gly Negative
Novel 46 A del Exon 4 –
8 M/8 AML-
MDS
M5 HR 46, XX Rs
12498609
86 G > C Exon 3 Pro-
Arg
– – – – Novel 1347 T del Exon 8 Gly- Gly Positive
Novel 1842 G del Exon 3 Gly-
Gly
Novel 1111
T > C
Exon 8 Try-His
Novel 46 A del Exon 4 –
HR high risk; SR standard risk; FAB French–American–British classification.
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Detection of TET2, KRAS and CBL variants by Next Generation Sequencing and analysis 213Fluorescence in situ hybridization (FISH) was performed
on interphase nuclei and metaphase chromosomes of bone
marrow cells using dual-color/dual-fusion probes for translo-
cations of inv (16;16), t(9;22), t(4;14), chromosome 19, and
dual-color/deletion probe for del 7q, labeled in green and red
spectra according to the manufacturer’s protocol provided
by Cytocell, UK. Counterstaining was performed with 40,6-dia
midino-2-phenylindole (DAPI). At least 100 nuclei were ana-
lyzed under the Fluorescence microscope, and image capture
was performed using Nikon Eclipse 80i equipped with a
CCD-camera (CoolCube1), appropriate filters and Isis soft-
ware (MetaSystems).2.3. DNA isolation and Next Generation Sequencing
Blood samples were collected with EDTA (Ethylenediaminete-
traacetic acid)-containing tubes and DNA was extracted from
peripheral blood and bone marrow leukocytes with MagNA
Pure automatic DNA isolation instrument (Roche Diagnos-
tics, Manheim, Germany).
We used NGS to study three candidate genes at TET2,
KRAS and CBL. All coding exons of TET2 (exons 3 and 11)
were presented by 27 amplicons. Besides, two primer pairs
were amplified known mutational hotspot regions to describe
the RING finger domain and linker sequence for CBL (exons
8 and 9) and KRAS (exons 2 and 3). The analyses were per-
formed as previously described by Kohlmann et al. [18].
Next Generation Sequencing was carried out using 454 GS
Junior System Instrument Roche Applied Science. The Data
were analyzed using the GS Amplicon Variant Analyzer soft-
ware version 2.3. (Roche Applied Science, Germany). We used
filters which were adjusted to show variants in more than 1%
of bidirectional reads per amplicon and per patient to deter-
mine the variants.Figure 1 Distribution of generated am2.4. Real time PCR
FLT3-ITD and JAK V 617 F mutation were analyzed by Real
Time PCR on Light Cycler 480 II instrument (Roche Diagnos-
tics, Gmbh, Mannheim, Germany). Results were analyzed with
the High Resolution Melting (HRM) method using genotype
profiles. Different plots were created by selecting negative con-
trols as the base-line. Therefore, fluorescence of the all other
samples was diagramed relative to this sample. Fluorescence
signals were analyzed and significant differences used as indi-
cators of mutations [17,19].
3. Results
In this study, we analyzed mutations affecting the TET2 cod-
ing sequence (exons 3–11), KRAS (exons 2–3) and CBL (exons
8–9) in our patients with pediatric AML. In total, 20 variants
were detected by NGS mutation screening method. The results
are shown in Table 1. We detected 16 variants in TET2, two
variants both KRAS and CBL genes. Table 1 shows the sum-
mary of the association of patients’ characteristics and variants
of TET2, KRAS and CBL profiles.
Karyotype analysis was normal in three of the eight
(37.5%) patients. Trisomy 14, Trisomy 19, Trisomy 22, mono-
somy 7, monosomy 14, inv (16;16), t(9;22) were found using
chromosome banding and FISH analyses. We screened all
patients during treatment or relapse. While one patient had 6
TET2, 1 KRAS gene variants, the other patient had 7 TET2
variants. Two relapse patients (number 4 and 5) had the same
CBL variants.
Fig. 1 displays distribution of amplicon reads for patients.
The most of TET2 variants were described in the largest exon
3 and 11; 1842 G > -(6/8 patients, 75%) and 1088 C > T(5/8,
62.5%) variants, 5162 T > G(5/8, 62.5%) in exon 3 and exonplicon sequence reads per patient.
214 D.F. Akin et al.11 of TET2 gene, respectively. 310 A > C(7/8 87.5%) varia-
tion was the highest among the variants in intron 2 of KRAS
gene. 1347 T > -in exon 8 of CBL gene was detected in 6
out 8 patients (75%).
All of AML patients were found negative for JAK V617 F.
Three (37.5%) of the eight patients were only FLT3-ITD
mutation positive.4. Discussion
AML is a heterogeneous disorder of hematopoietic stem cells,
characterized by multiple genetic events which have an impact
on proliferation and differentiation. Some of the genetic and
epigenetic alterations play a major role in leukemogenesis;
gene mutations, deletions, translocations, and DNA methyla-
tion. Recent studies have reported that several genes such as
TET2, KRAS, CBL, FLT3, JAK2 involve in the pathogenesis
of AML [1,3,6,10,11,18]. Activated TET2, RAS and CBL
mutations confer proliferative and survival signals.
In this study, we screened the mutations of TET2, KRAS
and CBL genes in childhood AML patients. We used an ampli-
con based sequencing method to find possible new genetic
markers for leukemia diagnosis. TET2, KRAS and CBL genes
were selected based on recent studies on genetic abnormalities
in AML and other hematologic malignancies. In all patients,
we reported novel mutations at TET2 and CBL genes. 7 of
16 substitutions were missense mutations in the exon and
UTR (Untranslated region). These mutations may result in
truncated translation of protein.
There are very few studies in childhood AML regarding
TET2 mutations. The frequency of TET2 mutations have been
reported to be lower in childhood AML when compared with
the adult AML [20]. Coenen et al. have performed PCR and
sequencing analyses in order to compare childhood AML with
the adult AML. They have shown that the frequency of CBL
was similar (1–2%). Sano et al. have presented a study using
PCR and sequencing analyses and have shown that 29
(18.5%) of the 157 childhood AML patients carried RAS
mutations [3]. However, RAS mutations were reported
25–44% in adult AML [8–10].
In this study, we found 16 variants of which 7 of them are
novel. The variants were found to be localized from exon 3 to
exon 11 in TET2 gene (Fig. 2). Metzeler et al. demonstrated
that the patients with favorable risk (according to European
Leukemia Net (ELN)) and carrying TET2 mutations had
lower response ratios and higher risk of relapse or death when
compared to the patients with TET2 wild type [6]. TET2Figure 2 Localization of sequence variationsmutations that have frame shift, nonsense and missense muta-
tions are acquired JAK2 mutations [2]. Our data suggest that
TET2 variants are more frequent than CBL and KRAS
variants in childhood AML.
Mutant CBL affects oncogenic phenotype in different cell
lines and induces growth factor independence. Schnittger
et al. analyzed 636 patients (MPN/MDS, seconder AML,
CMML (Chronic Myelomonocytic Leukemia) and showed
several CBL mutations localized in LINKER and RING
domains in their study group. In addition, the frequency of
CBL mutations was reported to be higher in patients with
mutated JAK2 V617 F when compared to the patients with
JAK2 V617 wild type [21]. Reindl et al. have detected exons
8 and 9 deletion transcripts of CBL in three of 279 AML/
MDS patients. In PCR screening of AML/MDS patients,
one of 116 patients carried a substitution of arginine to glycine
at position 420. In addition, PCR screening revealed loss of the
transcripts of mutant CBL lacking exons 8 and 9 in remission
samples [11].
Several studies have shown that CBL promoted down-
regulation of FLT3 activity. Sargın et al. searched the role of
c-Cbl in FLT3 regulation and showed that deregulated FLT3
activity has significant roles in AML pathogenesis [22]. Reindl
et al. revealed that four of 279 AML/MDS patients were found
positive for expression of abnormal CBL transcripts, and
hypothesized that CBL mutations might cause the high
FLT3 expression and activation of abnormal FLT3 [11]. In a
previous study, CBL variants have been detected at the rate
of 1–2% [25]. In our study we also confirmed that AML
patients had only two CBL variants.
Sano et al. studied 157 pediatric AML patients and
reported that RAS mutation frequency was higher in AML
M4–M5 types than other AML types [3]. Liang et al. searched
for mutations in the RAS gene in 130 pediatric AML patients.
KRAS mutation frequency was higher in MLL positive AML
patients than MLL negative AML patients; without statistical
significance (P= 0.069) [23]. Our screening results showed
that seven of the eight patients (87.5%) have the same novel
KRAS variant (1347 T del), and one patient has two novel
variants (1347 T del and 1111 T > C). Relapse patients (num-
ber 4 and 5) are showing the same 3 novel TET2 variants, and
same KRAS and CBL variants. In addition, they present
FLT3-ITD positivity.
We think that 1347 T del (novel KRAS variant) and 1842 G
del, 46 A del, 730 A del (3 novel TET2 variants) could be
important prognostic markers for childhood AML/relapse
patients and should need further study in a larger group of
patient.in relation to the TET2 coding sequence.
Detection of TET2, KRAS and CBL variants by Next Generation Sequencing and analysis 2155. Conclusion
In conclusion, TET2 mutations are more frequent than KRAS,
and CBL mutations in pediatric AML. In addition, TET2,
KRAS, and CBL may potentially be genetic markers for leuke-
mia diagnosis. However, these results need to be confirmed by
further studies on a larger number of patients.
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